Improving the ODT experience

Published: 13-Feb-2012
Ingredients Drug Delivery Analysis Pharmaceutical Dosage Forms

Results from a pilot study carried out by Cargill Pharma to assess the performance of Zerose erythritol as an orally dispersible tablet (ODT) excipient for unpalatable active ingredients compared with mannitol showed that Zerose erythritol outperforms mannitol in the areas of dilution potential, disintegration profile and taste masking.

You need to be a subscriber to read this article.
Click here to find out more.

Orally dispersible tablets are a dosage form in which taste and mouth feel are key. Liesbeth Meeus, Cargill Pharma & Personal Care Application Centre Leader, describes a pilot study looking at the use of Zerose erythritol in ODTs,

Excipients play an increasingly strategic role in the development of new pharma products by helping to deliver the actives and extend the life-span of existing products through novel formulations and dosage forms.1

Cargill Pharma recently announced results from a pilot study designed to assess the performance of Zerose erythritol as an orally dispersible tablet (ODT) excipient for unpalatable active ingredients compared with mannitol.

The following excipients were used:

  • Zerose erythritol (Cargill)
  • C*PharmIsoMaltidex, isomalt (Cargill)
  • C*PharmMannidex, mannitol (Cargill)
  • Magnesium stearate (Merck)

L-ascorbic acid (Prolabo) was used as an active ingredient.

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
See more

You may also like

Ingredients

Cargill invests US$15m in alginates business expansion in France

Read more
Aims to provide sustainable supply of high quality alginates for pharma and food markets

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. Suncombe and Kindeva collaborate to deliver low-carbon inhalers to the NHS The partnership will develop next-generation pressurised metered-dose inhalers with low Global Warming Potential propellants, helping the NHS move closer to its Net Zero target
  3. ProMach Pharma presents new equipment at Pack Expo Las Vegas Several new systems will be on exhibit for the first time, alongside other advanced processing and packaging equipment for pharmaceuticals, biopharmaceuticals, nutraceuticals, medical devices and more
  4. Bavarian Nordic launches chikungunya vaccine Vimkunya in the UK The UK announcement of the recombinant vaccine follows recent approval by the MHRA in May 2025
  5. Quotient Sciences and CPI to accelerate RNA drug development with joint venture Quotient Sciences and UK technology innovation centre, CPI, have signed a memorandum of understanding (MoU) to form a Joint Venture (JV) aimed at accelerating the development of RNA-based therapies

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Ingredients

Cargill invests US$15m in alginates business expansion in France

Aims to provide sustainable supply of high quality alginates for pharma and food markets
Ingredients

Evolva and Cargill to co-develop steviol glycosides

Cargill will make a US$5.3m investment in Evolva
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Problem-solving ingredients for complex drugs

Around 40% of new chemical entities fall into class II – low solubility drugs, making them difficult to formulate. Improving the bioavailability of these compounds is a major challenge but the technologies involved could help to extend the lifecycle of many medicines. Manufacturers are also looking to improve palatability and diversify drug delivery routes to increase patient compliance.
Ingredients

Scottish grant for BASF plant on Isle of Lewis

Expansion will safeguard existing jobs and create up to 98 new positions
Ingredients

CPhI News: Cargill study will show Zerose erythritol versatility

Cargill Pharma will release new data soon illustrating the versatility of its excipient
Ingredients

CPhI NEWS: Cargill launches new tablet flavour technology

The Maxens technology offers a better, long lasting flavour with cost and process efficiencies for compressed tablets
Ingredients

Good taste in excipients

Polyol erythritol is becoming a valuable diluent option for chewable tablets thanks to its taste-masking properties. Liesbeth Meeus, Application Centre Leader for Cargill Pharma & Personal Care EMEA, describes new wet granulation techniques using Zerose erythritol
Subscribe now